Unum Therapeutics has developed a strategy to advance our platforms and product candidates towards the clinic, with the goal of addressing many more cancer targets and treating more tumor types. We focused our pipeline to provide the best path forward in advanced solid tumors, which we believe represents the greatest unmet medical need for targeted cell therapies.
Click on a study below to learn more about its progress.
Non-Hodgkin Lymphoma (NHL): ACTR707 + rituximab
Learn more about the Phase 1 clinical trial in patients with relapsed or refractory non-Hodgkin lymphoma called ATTCK-20-03 here.
GPC3+ Solid Tumor Cancers: BOXR1030
BOXR1030 is the first product candidate from the BOXR platform and is currently in preclinical development. BOXR1030 is engineered to specifically target tumor cells expressing an oncofetal antigen called glypican-3, also known as GPC3. This antigen is expressed in several solid tumor indications, including hepatocellular carcinoma and squamous cell lung cancer. A characteristic of these particular solid tumors is their enhanced metabolic activity, leading to depletion of free nutrients, like glucose, from their local environment. Nutrient competition within tumor microenvironments is a form of immune suppression, and can limit the ability of T cells to kill, proliferate, and exert anti-tumor activity.
BOXR1030 contains the novel “bolt-on” enzyme called glutamic-oxaloacetic transaminase 2 (GOT2) that aims to improve intrinsic T cell function in the solid tumor microenvironment through enhanced metabolism. GOT2 plays a central metabolic role by linking multiple pathways involved in biosynthesis and cellular energy production. In our preclinical studies representing the immunosuppressive tumor microenvironment, GOT2 displayed pleiotropic effects on BOXR1030 T cells, dramatically improving anti-tumor activity beyond that achieved with traditional CAR-T cells.